BackSAB Biotherapeutics Overview

SAB Biotherapeutics Receivables

SAB Biotherapeutics's receivables is $1.8M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.84M

Peer trimmed avg / median

Loading

SAB Biotherapeutics Receivables History

Loading

SAB Biotherapeutics vs. peers: Receivables Comparison

Loading

SAB Biotherapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

SAB Biotherapeutics (SABS) FAQ

SAB Biotherapeutics posts a receivables of $1.8M as of June 2026. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, SAB Biotherapeutics's receivables was $0. The latest reading is $1.8M (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of SAB Biotherapeutics's financial statement story. At $1.8M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SABS's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; SAB Biotherapeutics's other metric pages and overview cover the third.